biosimilar


Also found in: Medical, Wikipedia.

bi·o·sim·i·lar

 (bī′ō-sĭm′ə-lər)
adj.
Highly similar in function and effect to an existing biological product, especially to a biologic that has already been clinically tested and approved for use.
n.
A biological product that is biosimilar to an existing product, especially to a biologic.
References in periodicals archive ?
M2 PHARMA-September 4, 2019-Sandoz announces global commercialisation deal for multiple sclerosis biosimilar natalizumab
M2 EQUITYBITES-September 4, 2019-Sandoz announces global commercialisation deal for multiple sclerosis biosimilar natalizumab
Global Banking News-September 3, 2019-Polpharma Biologics signs global commercialisation agreement for biosimilar Natalizumab for MS
Fact.MR has announced the addition of the "Pegfilgrastim Biosimilar Market Forecast, Trend Analysis & Competition Tracking - Global Review 2018 to 2028"report to their offering.
Coherus BioSciences is a leading biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets.
As prescription drug costs continue to increase, biosimilar medicines represent hope for patients seeking access to more affordable treatment.
M2 PRESSWIRE-July 29, 2019-: Biosimilar Market Trends Report 2019: EU Guidelines, US Guidelines, Interchangeability, Patent and Patent Dance Issues
Amgen (AMGN) and Allergan (AGN) announced that Mvasi, a biosimilar to Avastin, and Kanjinti, a biosimilar to Herceptin, are now available in the United States.
(Alliance News) - US biopharmaceutical firm Amgen Inc said Thursday two of its biosimilar cancer treatments are now available in the US.
* Biogen's three biosimilar treatments--BENEPALI[TM] (etanercept), FLIXABI[TM] (infliximab) and IMRALDI[TM] (adalimumab)--are estimated to save the European healthcare system 1.8 billion euros in 2019
Effective October 10, 2018, agreements between brand and biosimilar drug manufacturers regarding the manufacture, marketing, and sale of biosimilar versions of reference drug products must be filed with the FTC and the DOJ.
The agreement covers multiple biosimilar candidates from Samsung Bioepis, including third-wave biosimilar candidates SB11 and SB12, which reference Lucentis (ranibizumab) and Soliris (eculizumab), respectively, as well as SB3, a biosimilar candidate referencing Herceptin 3 (trastuzumab).